Latest news : Gamida Cell Ltd.

26/05/25	Gamida Cell Ltd. cancelled the acquisition of bluebird bio, Inc. from BlackRock, Inc., The Vanguard Group, Inc. and others.	CI
22/07/24	HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO	MT
18/06/24	Gamida Cell Names Rory Nealon as Chief Financial Officer	CI
18/06/24	Gamida Cell Names Sheila Frame as Chief Commercial Officer	CI
18/06/24	Gamida Cell Ltd. Names Joe Wiley as Chief Executive Officer	CI
17/06/24	Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC	CI
23/05/24	Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
09/04/24	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI
04/04/24	Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	CI
28/03/24	Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	MT
28/03/24	Top Premarket Decliners	MT
27/03/24	Top Midday Decliners	MT
27/03/24	Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	MT

More news

Analysts' recommendations: Gamida Cell Ltd.

29/01/24	JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	MT
15/11/23	Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	MT
15/11/23	HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	MT
19/05/23	JMP Securities Adjusts Price Target on Gamida Cell to $6 From $8, Keeps Market Outperform Rating	MT
16/05/23	Oppenheimer Adjusts Gamida Cell Price Target to $6 From $8, Maintains Outperform Rating	MT

More recommendations

Press Releases: Gamida Cell Ltd.

27/03/24	Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management	AQ
27/03/24	Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update	AQ
22/03/24	Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results	AQ
23/02/24	Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®	AQ
29/01/24	Gamida Cell Actively Pursuing Strategic Alternatives	AQ

More press releases

Managers and Directors: Gamida Cell Ltd.

Manager	Title	Age	Since
Joe Wiley CEO	Chief Executive Officer	55	-
Heayoung Shin CTO	Chief Tech/Sci/R&D Officer	-	31/05/2021
Rory Nealon COO	Chief Operating Officer	58	23/05/2024

Director	Title	Age	Since
Joe Wiley CHM	Chairman	55	-
George Hampton BRD	Director/Board Member	56	31/03/2019

More insiders

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The Company's clinical pipeline products include: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Employees

147

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Delayed OTC Markets Other stock markets 17:54:51 24/05/2024 BST			5-day change	1st Jan Change
0.0170 ^USD	+2.41%		-.--%	-

Market Cap	2.62M 2.3M 2.14M 1.97M 3.69M 251M 3.74M 25.47M 9.95M 124M 9.83M 9.62M 429M	P/E 2022	-1.04x	P/E 2023	-0.72x
Enterprise Value	39.01M 34.29M 31.92M 29.32M 55.05M 3.74B 55.77M 379M 148M 1.85B 146M 143M 6.38B	EV / Sales 2022	-	EV / Sales 2023	51,081,230x
Free-Float	89.41%	Yield 2022 *	-	Yield 2023	-

3 years	0.01	1.47
5 years	0.01	5.91
10 years	0.01	15.41

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/01/24	Ronit Simantov	Free	Chief Technology Officer	480,319	0.3621%
31/01/24	Kenneth Moch	Free	Director	200,000	0.1508%
31/01/24	Stephen Wills	Free	Director	200,000	0.1508%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GAMIDA CELL LTD.	+2.41%	-.--%	-.--%	-98.71%	2.62M
ARGENX SE	-1.11%	+2.66%	+52.48%	+71.89%	56.19B
WUXI APPTEC CO., LTD.	-0.27%	+0.35%	+40.26%	+79.88%	54.83B
BIONTECH SE	+1.97%	-1.16%	-21.00%	-13.25%	23.04B
INSMED INCORPORATED	-2.05%	-2.14%	+0.75%	+413.38%	22.7B
WUXI BIOLOGICS (CAYMAN) INC.	-0.21%	-0.62%	+20.56%	-10.90%	20.23B
GENMAB A/S	-0.89%	+1.75%	+25.88%	-30.37%	17.83B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.97%	-0.59%	+33.12%	+550.67%	15.65B
PHARMAESSENTIA CORPORATION	+5.29%	+1.70%	+185.09%	+333.94%	15.24B
EXELIXIS, INC.	+0.79%	+0.50%	+22.39%	+184.74%	14.03B
Average	+0.49%	+1.15%	+35.95%	+148.13%	23.97B
Weighted average by Cap.	-0.11%	+1.07%	+38.45%	+137.80%

Gamida Cell Ltd. Share Price

Stocks

GMDA

IL0011552663

Biotechnology & Medical Research

Valuation: Gamida Cell Ltd.

Latest news : Gamida Cell Ltd.

Analysts' recommendations: Gamida Cell Ltd.

Press Releases: Gamida Cell Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Gamida Cell Ltd.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

	2022	2023
Net sales	-	1.78 1.57 1.46 1.34 2.52 171.08 2.55 17.35 6.78 84.48 6.7 6.55 291.99
Net income	-79.38M -69.78M -64.95M -59.65M -112M -7.61B -113M -772M -302M -3.76B -298M -292M -12.99B	-63M -55.38M -51.55M -47.34M -88.9M -6.04B -90.07M -613M -239M -2.98B -236M -231M -10.31B
Net Debt	39.31M 34.56M 32.17M 29.54M 55.47M 3.77B 56.2M 382M 149M 1.86B 148M 144M 6.43B	36.39M 31.99M 29.78M 27.35M 51.35M 3.49B 52.03M 354M 138M 1.72B 137M 134M 5.96B